Tamoxifen and gallstone formation in postmenopausal breast cancer patients: Retrospective cohort study

World Journal of Surgery

Volumn 27, Issue 4, 2003, Pages 395-399

  Akin, Mehmet L ^a   Uluutku, Haldun ^a   Erenoglu, Cengiz ^a   Karadag, Ahmet ^a   Gulluoglu, Bahadir M ^b   Sakar, Burak ^c   Celenk, Tuncay ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ABDOMEN; ADULT; AGE; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PATIENT; CANCER REGISTRY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; FOLLOW UP; GALLSTONE FORMATION; HUMAN; INCIDENCE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PREMENOPAUSE; RETROSPECTIVE STUDY; REVIEW; TIME; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHOLELITHIASIS; COHORT STUDIES; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; POSTMENOPAUSE; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 0043245879     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-002-6468-4     Document Type: Article

References (33)

1. Osborne CK. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 1998;339:1609-1618
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. 1998;90:1371-1388
4. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant trial: the Scottish Breast Cancer Committee. Br. J. Cancer 1991;303:435-437
5. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 1996;14:78-84
6. Vrscaj MU, Kovacic J, Bebar S, et al. Endometrial and other cancers after tamoxifen treatment of breast cancer: results of retrospective cohort study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001;95:105-110
7. Williams GM, Iatropoulos MJ, Djordjevic MV, et al. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993;14:315-317
8. Uhler ML, Marks JW, Voigt BJ, et al. Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women. J. Clin. Endocrinol. Metab. 1998;83:410-414
9. Lum SS, Woltering EA, Fletcher WS, et al. Changes in serum estrogen levels in women during tamoxifen therapy. Am. J. Surg. 1997;173:399-402
10. Weigley ES. Adolphe Quetelet (1796-1874): pioneer anthropometrist. Nutr. Today 1989;24:12-16
11. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet. Gynecol. 1994;83:5-11
12. Lonning PE, Lien EA, Lundgren S, et al. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin. Pharmacokinet. 1992;22:327-358
13. Pommier RF, Woltering EA, Keenan EJ, et al. The mechanism of hormone-sensitive breast cancer progression on antiestrogen therapy: implications for treatment and protocol planning. Arch. Surg. 1987;122:1311-1316
14. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: the Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 1993;85:1398-1406
15. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994;86:527-537
16. Pathak DN, Bodell WJ. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 1994;15:529-532
17. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J. Clin. Oncol. 1991;9:1740-1748
18. Small DM. The etiology and pathogenesis of gallstones. Adv. Surg. 1976;10:63-85
19. Carey MC. Formation of gallstones: the new paradigms. In Paumgartner G, Stiehl A, editors, Trends in Bile Acid Research, London, Dordrecht, 1988;259-281
20. Lynn J, Williams L, O'Brien J, et al. Effects of estrogen upon bile: implications with respect to gallstone formation. Ann. Surg. 1973;178:514-524
21. Heuman R, Larsson-Cohn U, Hammar M, et al. Effects of postmenopausal ethinylestradiol treatment on gallbladder bile. Maturitas 1980;2:69-72
22. Chen A, Huminer D. The role of estrogen receptors in the development of gallstones and gallbladder cancer. Med. Hypotheses 1991;36:259-260
23. Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall-bladder disease, and breast tumours. Lancet 1973;1:1399-1404
24. Henriksson P, Einarsson K, Eriksson A, et al. Estrogen-induced gallstone formation in males: relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma. J. Clin. Invest 1989;84:811-816
25. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N. Engl. J. Med. 1974;290:15-19
26. LaMorte WW, Schoetz DJ Jr, Birkett DH, et al. The role of the gallbladder in the pathogenesis of cholesterol gallstones. Gastroenterology 1979;77:580-592
27. Ranelletti FO, Piantelli M, Farinon AM, et al. Estrogen and progesterone receptors in the gallbladders from patients with gallstones. Hepatology 1991;14:608-612
28. Singletary BK, Van Thiel DH, Eagon PK. Estrogen and progesterone receptors in human gallbladder. Hepatology 1986;6:574-578
29. Yamamoto M, Nakajo S, Tahara E. ImmunohistochemicaI analysis of estrogen receptors in human gallbladder. Acta Pathol. Jpn. 1990;40:14-21
30. Everhart JE, Khare M, Hill M, et al. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999;117:632-639
31. Attili AF, Carulli N, Roda E, et al. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.). Am. J. Epidemiol. 1995;141:158-165
32. Erdem H, Mas MR, Baysan A, et al. The prevalance of cholelithiasis in Mid-Anatolia [abstract 56]. Presented at the Falk workshop on hepatobiliary diseases: cholestasis and gallstones, Cluj-Napoca, Romania, 2000
33. Floren LC, Hebert MF, Venook AP, et al. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Ann. Oncol. 1998;9:1123-1126